Cardiovascular disease in patients with chronic kidney disease

Seminars in Nephrology

Volumn 22, Issue 6, 2002, Pages 459-473

  Jaradat, Majd I ^a   Molitoris, Bruce A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANEMIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIALYSIS; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MORBIDITY; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; CHRONIC KIDNEY FAILURE; PATHOPHYSIOLOGY; PREVALENCE; RENAL REPLACEMENT THERAPY;

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANEMIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; PREVALENCE; RENAL REPLACEMENT THERAPY; RISK FACTORS;

EID: 0036849857     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1053/snep.2002.35964     Document Type: Article

References (113)

1. Levey AS, Beto JA, Coronado BE, et al: Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Am J Kidney Dis 32:853-906, 1998
2. USRDS: Annual Data Report V. Patient mortality and survival. Am J Kidney Dis 32:S69-S80, 1998 (suppl 1)
3. National Kidney Foundation Task Force on Cardiovascular Disease: Controlling the epidemic of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:S1-S199, 1998 (Suppl 3)
4. Foley RN, Parfrey PS, Harnett JD, et al: Clinical and echocardiographic disease in patients starting end stage renal disease therapy. Kidney Int 47:186-192, 1995
5. Parfrey PS, Foley RN, Harnett JD, et al: The outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplant 11:1277-1285, 1996
6. Foley RN, Parfrey PS: Complications of long term dialysis: Cardiovascular complications of cardiac risk factor interventions, in Brown E, Parfrey P (eds): Complications of Long Term Dialysis. Oxford, Oxford University Press, 1999, pp 29-52
7. Levin A, Thompson CR, Ethier J, et al: Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 34:125-134, 1999
8. Jungers P, Khoa TN, Massy ZA, et al: Incidence of atherosclerotic arterial occlusive accidents in predialysis and dialysis patients: A multicentric study in the Ile de France district. Nephrol Dial Transplant 14:898-902, 1999
9. Culleton BF, Larson MG, Wilsom PWF, et al: Cardiovascular disease and mortality in a community based cohort with mild renal insufficiency. Kidney Int 56:2214-2219, 1999
10. Chertow GM, Normand S-LT, Silva LR, et al: Survival after acute myocardial infarction in patients with end stage renal disease: Results from the Cooperative Cardiovascular Project. Am J Kidney Dis 35:1044-1051, 2000
11. Herzog CA: Poor long term survival of dialysis patients after acute myocardial: Bad treatment or bad disease? Am J Kidney Dis 35:1217-1220, 2000
12. Mann J, Gerstein HC, Pogue J: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 134: 629-636, 2001
13. Hemmelgarn BR, Ghali WA, Quan H: Poor long term survival after coronary angiography in patients with renal insufficiency. Am J Kidney Dis 37:64-72, 2001
14. Beattie JN, Soman SS, Sandberg KR: Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. Am J Kidney Dis 37:1191-1200, 2001
15. Foley RN, Parfrey PS, Harnett JD, et al: Impact of hypertension on cardiomyopathy, morbidity and mortality in end stage renal disease. Kidney Int 49:1379-1385, 1996
16. O'Riordan E, Foley RN: Effects of anemia on cardiovascular status. Nephrol Dial Transplant 15:19-22, 2000
17. Levin A, Foley RN: Cardiovascular disease in chronic renal insufficiency. Am J Kidney Dis 36:24-30, 2000
18. Block GA, Port FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 35:1226-1237, 2000
19. Pannier B, Guerin AP, Marchais SJ, et al: Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end stage renal disease. Kidney Int 57:1091-1099, 2000
20. Goodman WG, Goldin J, Kuizon BD: Coronary artery calcification in young adults in end stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483, 2000
21. Amann K, Ritz E, Weist G, et al: A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 4:1814-1819, 1994
22. Sarnak MJ, Levey AS: Cardiovascular disease and chronic renal disease: A new paradigm. Am J Kidney Dis 35:S117-S131, 2000 (suppl 1)
23. Levin A, Siger J, Thompson CR, et al: Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 27:347-354, 1996
24. Silberg JS, Barre PE, Prichard SS, et al: Impact of left ventricular hypertrophy on survival in end stage renal disease. Kidney Int 36:268-290, 1989
25. Locatelli F, Marcelli D, Conte F, et al: Patient selection affects end stage renal disease outcome comparisons. Kidney Int 57:S94-S99, 2000 (suppl 74)
26. Foley RN, Parfrey PS, Harnett, et al: The impact of anemia on cardiomyopathy, morbidity and mortality in end stage renal disease. Am J Kidney Dis 28:53-61, 1996
27. Foley RN, Parfrey PS, Kent GM, et al: Serial change in echocardiographic parameters and cardiac failure in end stage renal disease. J Am Soc Nephrol 11:912-916, 2000
28. Foley RN, Parfrey PS: Cardiovascular disease and mortality in ESRD. J Nephrol 11:239-245, 1998
29. London GM, Fabiani F, Marchais SJ, et al: Uremic cardiomyopathy: An inadequate left ventricular hypertrophy. Kidney Int 31:973-980, 1987
30. London G, Parfrey PS: Cardiac disease in chronic uremia: Pathogenesis. Adv Ren Replace Ther 4:194-211, 1997
31. Hunter JJ, Chien KR: Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 341:1276-1283, 1999
32. Amann K, Kronenberg G, Gehlen F, et al: Cardiac remodeling in experimental renal failure - An immunohistochemichal study. Nephrol Dial Transplant 13:1958-1966, 1998
33. Murphy SW, Foley RN, Barrett BJ, et al: Comparative hospitalization of hemodialysis and peritoneal dialysis patients in Canada. Kidney Int 57:2557-2563, 2000
34. Hayashi T, Suzuki A, Shoji T, et al: Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 35:250-256, 2000
35. Portoles J, Torralbo A, Martin P, et al: Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 29:541-548, 1997
36. Silverberg D, Wexler D, Blum M, et al: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35:1737-1744, 2000
37. Garcia DL, Anderson S, Rennke HG, et al: Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci U S A 85:6142-6146, 1988
38. Lafferty HM, Garcia DL, Rennke HG, et al: Anemia ameliorates progressive renal injury in experimental DOCA-salt hypertension. J Am Soc Nephrol 1:1180-1185, 1991
39. Omayama K: Effects of human recombinant erythropoietin on anemia and renal failure in predialysis patients. Nephrol Dial Transplant 4:966-970, 1989
40. Abraham PA, Opsahl JA, Rachael KA, et al: Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients. Am J Nephrol 10: 128-136, 1990
41. Lim VS, Frangmen J, Flanigan MJ, et al: Effects of recombinant human erythropoietin on renal function in humans. Kidney Int 37:131-136, 1990
42. Roth D, Smith RD, Schulman G, et al: Effects of rHuEpo on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 24:777-784, 1994
43. Kuriyama S, Tomonari H, Yoshida H, et al: Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77:176-185, 1997
44. Krmar TR, Gretz N, Klare B, et al: Renal function in predialysis children with chronic renal failure treated with Epo. Pediatr Nephrol 11:69-73, 1997
45. Jungers P, Choukroun G, Oualim Z, et al: Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 16:307-312, 2001
46. Ritz E, Eisenhardt A: Early epoietin treatment in patients with renal insufficiency. Nephrol Dial Transplant 15:40-44, 2000 (suppl 3)
47. Albertazzi A, Di Liberato L, Daniele F, et al: Efficacy and tolerability of recombinant human erythropoietin treatment in predialysis patients: Results of a multicenter study. Int J Artif Organs 21:12-18, 1998
48. Massimetti C, Pontillo D, Feriozzi S, et al: Impact of recombinant human erythropoietin treatment on lf ventricular hypertrophy and cardiac function in dialysis patients. Blood Purif 16:317-324, 1998
49. Jeren-Strujic B, Raos V, Jeren T, et al: Morphologic and functional changes of left ventricle in dialyzed patients after treatment with recombinant human erythropoietin. Angiology 51:131-139, 2000
50. Fink JC, Blahut S, Reddy M, et al: Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 37:348-355, 2001
51. Valderrabano F: Improvement and prevention of left ventricular hypertrophy in predialysis patients. Nephrol Dial Transplant 15:A115, 2000
52. Revicki DA, Brown E, Feeny DH, et al: Health related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25:458-554, 1995
53. Harnett JD, Parfrey PS: Blood pressure control and regression of LV hypertrophy in dialysis patients. Contrib Nephrol 106:110-113, 1994
54. Besarab A, Bolton WK, Browne JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoietin. N Engl J Med 339:584-590, 1998
55. Jacobs C: Normalization of hemoglobin: Why not? Nephrol Dial Transplant 14:75-79, 1999 (suppl 2)
56. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, et al: Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. J Am Soc Nephrol 11:335-342, 2000
57. Collins AJ, Li S, St Peter W, et al: Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 12:2465-2473, 2001
58. Perneger T, Whelton P, Klag MJ: History of hypertension in patients treated for end stage renal disease. J Hypertens 15:451-456, 1997
59. Buckalew VM, Berg RL, Wang S-R, et al: Prevalence of hypertension in 1,795 subjects with chronic renal disease: The modification of diet in renal disease study baseline cohort. Am J Kidney Dis 28:811-821, 1996
60. Foley RN, Parfrey PS: Cardiac disease in chronic uremia: Clinical outcome and risk factors. Adv Ren Replace Ther 4:234-248, 1997
61. Desgupta I, Madeley RJ, Pringle MAL, et al: Management of hypertension in patients developing end stage renal failure. QJM 92:519-525, 1999
62. Klag MJ, Whelton PK, Randall BL, et al: Blood pressure and end stage renal disease in men. N Engl J Med 334:13-18, 1996
63. Hansson L, Zanchetti A, Carruthers SG, et al: Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: Principal results of the Hypertension Optima Treatment (HOT) randomized trial. Lancet 351: 1755-1762, 1998
64. Ruggenenti P, Perna A, Benini R, et al: In chronic nephropathies prolonged ACE inhibition can induce remission: Dynamics of time-dependent changes in GFR. J Am Soc Nephrol 10:997-1006, 1999
65. Locatelli F, Del Vecchio L: How long can dialysis be postponed by low protein diet and ACE inhibitors? Nephrol Dial Transplant 14:1360-1364, 1999
66. Ambrosioni E, Borghi C, Magnani B, et al: The effect of the angiotensin converting enzyme inhibitor zofinopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long Term Evaluation (SMILE) study investigators. N Engl J Med 332:80-85, 1995
67. Flather MD, Yusuf S, Kober L, et al: Long term ACE inhibitor therapy in patients with heart failure and left ventricular dysfunction: A systematic overview of data from individual patients. Lancet 355:1575-1581, 2000
68. Yusuf S, Sleight P, Pogue J, et al: Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153, 2000
69. Mann JF, Gerstein HC, Pogue J, et al: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 134:629-636, 2001
70. Ruilope LM, Aldigier JC, Ponticelli C, et al: Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 18:89-95, 2000
71. Remuzzi G, Schieppati A, Ruggenenti P: Nephropathy in patients with type 2 diabetes. N Engl J Med 346:1145-1151, 2002
72. Pitt B, Segal R, Martinez FA, et al: Randomised trial of Losartan versus Captopril in patients over 65 with heart failure. Lancet 349:747-752, 1997
73. Stigant CE, Cohen J, Vivera M, et al: ACE inhibitors and angiotensin II antagonists in renal transplantation: An analysis of safety and efficacy. Am J Kidney Dis 35:58-63, 2000
74. Mogensen CE, Neldam S, Tikkanen I, et al: Randomized controlled trial of dual blockade of rennin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The Candesartan and Lisinopril Microalbuminuria (CALM) study. BMJ 321:1440-1444, 2000
75. Ruilope LM, Salvetti A, Jamerson K, et al: Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optima Treatment (HOT) study. J Am Soc Nephrol 12:218-255, 2001
76. Gaede P, Vedel P, Parving HH, et al: Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomized study. Lancet 357:1601-1608, 1999
77. Jono S, McKee MD, Murry CE, et al: Phosphate regulation of vascular smooth muscle calcification. Circ Res 87: E10-E17, 2000
78. Marchais SJ, Metivier F, Guerin AP, et al: Association of hyperphosphatemia with hemodynamic disturbances in end stage renal disease. Nephrol Dial Transplant 14:2178-2183, 1999
79. Braun J, Oldendorf M, Moshage W, et al: Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27:394-401, 1996
80. Amann K, Gross ML, London GM. et al: Hyperphosphatemis - A silent killer of patients with renal failure. Nephrol Dial Transplant 14:2085-2087, 1999
81. Block GA, Hulbert-Shearon TE, Levin NW, et al: Association of serum phosphorus and calcium phosphate x product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31:607-617, 1998
82. Raggi P, Callister TQ, Cooil B, et al: Identification of patients at increased risk of first unheralded acute myocardial infarction by electron beam computed tomography. Circulation 101:850-855, 2000
83. Raggi P, Boulay A, Chasan-Taber S, et al: Cardiac calcification in adult hemodialysis patients, a link between end stage renal disease and cardiovascular disease? Am Coll Cardiol 39:695-701, 2002
84. Rostand SG, Drueke TB: Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 56:383-392, 1999
85. Chertow GM, Dillon M, Burke SK, et al: A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 51:18-26, 1999
86. Bleyer AJ, Burke SK, Dillon M, et al: A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33:694-701, 1999
87. Antonsen JE, Sherrard DJ, Andress DL: A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication. Kidney Int 53:223-227, 1998
88. Goodman WG, Frazao JM, Goodkin DA, et al: A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 58: 436-445, 2000
89. Goodman WG, Hladik GA, Turner SA, et al: The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13:1017-1024, 2002
90. Kasiske BL: Hyperlipidemia in patients with chronic renal disease. Semin Dial 11:102-105, 1998
91. Schaefer EJ, Lamon-Fava S, Jenner JL, et al: Lipoprotein (a) levels and risk of coronary heart disease in men. JAMA 271:999-1003, 1994
92. Cressman MD, Heyka RJ, Paganini EP, et al: Lipoprotein (a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86:475-482, 1992
93. Mooser V, Marcovina SM, White Al, et al: Kringle-containing fragments of apolipoprotein (a) circulate in human plasma and are excreted into the urine. J Clin Invest 98:2414-2424, 1996
94. Kronenberg F, Utermann G, Dieplinger H: Lipoprotein (a) in renal disease. Am J Kidney Dis 27:1-25, 1996
95. Sechi LA, Zingaro L, De Carli S, et al: Increased serum lipoprotein (a) levels in patients with early renal failure. Ann Intern Med 129:457-461, 1998
96. Arnadottir M, Thysell H, Nilsson-Ehle P: Serum lipoprotein (a) concentration is increased in moderate renal failure. Nephron 72:712-713, 1996
97. De Lima JJG, Maranhao RC, Latrilha MDM, et al: Early elevation of lipoprotein (a) levels in chronic renal insufficiency. Ren Fail 19:145-154, 1997
98. Chauveau P, Chadefaux B, Coude M, et al: Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 43:S72-S77, 1993 (suppl 41)
99. Hultberg B, Andersson A, Sterner G: Plasma homocysteine in renal failure. Clin Nephrol 40:230-235, 1993
100. Arnadottir M, Hultberg B, Nilsson-Ehle P, et al: The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Invest 56:41-46, 1996
101. Van Guldener C, Janssen MJFM, Surachno J: Short term effect of kidney transplantation on plasma homocysteine in dialysis patients. Irish J Med Sci 164:22, 1995 (abstr)
102. Nygard O, Nordrehaug JE, Refsum H, et al: Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337:230-236, 1997
103. Bostom AG, Shemin D, Verhouf P, et al: Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. Arterioscler Thromb Vasc Biol 17:2554-2558, 1997
104. Moustapha A, Naso A, Nahlawi M, et al: Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end stage renal disease. Circulation 97:138-141, 1998
105. Duell PB, Malinow MR: Homocysteine: An important risk factor for atherosclerotic vascular disease. Curr Opin Lipidol 8:28-34, 1997
106. Dennis VW, Nurko S, Robinson K: Hyperhomocysteinemia: Detection, risk assessment, and treatment. Curr Opin Nephrol Hypertens 5:483-488, 1997
107. Bostom AG, Shemin D, Lapane KL, et al: High dose B vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 49:147-152, 1996
108. Perna AF, Ingrosso D, De Santo NG, et al: Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia. J Am Soc Nephrol 8:1899-1905, 1997
109. Ross R: Atherosclerosis - An inflammatory disease. N Engl J Med 340:115-126, 1999
110. Stenvinkle P, Heimburger O, Paultre F, et al: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55:1899-1911, 1999
111. Ridker PM, Cushman M, Stampher MJ, et al: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973-979, 1997
112. Hajrai KJ: Potential new cardiovascular risk factors: Left ventricular hypertrophy, homocysteine, lipoprotein (a), triglycerides, oxidative stress, and fibrinogen. Ann Intern Med 131:376-386, 1999
113. Galli F, Canestrari F, Buoncristani U: Biological effects of oxidant stress in hemodialysis: The possible roles of vitamin E. Blood Purif 17:79-94, 1999